Compugen (NASDAQ:CGEN) Upgraded at Truist Financial

Truist Financial upgraded shares of Compugen (NASDAQ:CGEN) to a strong-buy rating in a research report sent to investors on Wednesday,Zacks.com reports.

Other research analysts have also issued reports about the company. HC Wainwright initiated coverage on Compugen in a report on Wednesday, January 7th. They set a “buy” rating and a $4.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. Finally, Wall Street Zen raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $4.00.

Compugen Stock Performance

Shares of CGEN stock opened at $2.04 on Wednesday. Compugen has a 1 year low of $1.13 and a 1 year high of $2.38. The stock has a market cap of $192.88 million, a PE ratio of 5.51 and a beta of 2.90. The business’s fifty day moving average is $1.96 and its 200-day moving average is $1.75.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.55. The company had revenue of $67.33 million for the quarter, compared to the consensus estimate of $14.30 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%. Equities research analysts predict that Compugen will post -0.03 earnings per share for the current year.

Hedge Funds Weigh In On Compugen

A number of hedge funds have recently modified their holdings of CGEN. Franklin Resources Inc. acquired a new stake in shares of Compugen during the second quarter worth $56,000. Jane Street Group LLC lifted its holdings in shares of Compugen by 1,077.0% during the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock valued at $700,000 after purchasing an additional 359,785 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of Compugen by 346.0% in the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 34,045 shares during the period. Two Sigma Investments LP increased its stake in Compugen by 10.6% in the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 18,929 shares in the last quarter. Finally, Raymond James Financial Inc. increased its stake in Compugen by 51.0% in the 3rd quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 34,215 shares in the last quarter. 12.22% of the stock is currently owned by institutional investors and hedge funds.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.